Saturday, March 19, 2011

Hepatitis C Geno 5;Efficacy of interferon-based antiviral therapy

Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5:
A meta-analysis of two large prospective clinical trials

Fran├žois D'Heygere1, Christophe George1, Hans Van Vlierberghe2, Jochen Decaestecker3,
Antoine Nakad4, Michael Adler5, Jean Delwaide6, Annick Laureys7, Frederik Nevens8,*

Article first published online: 16 MAR 2011
DOI: 10.1002/jmv.22049

Keywords:hepatitis C;genotype 5;chronic hepatitis C;pegylated interferon


The characteristics and response rate to pegylated interferon and ribavirin (PEG-INF + RBV) of patients with chronic hepatitis C infected with genotype 5 are poorly documented. A meta-analysis of two large phase III/IV prospective randomized clinical trials conducted in Belgium in patients with chronic hepatitis C (n = 1,073 patients) was performed in order to compare the response to antiviral therapy of hepatitis C virus (HCV) genotype 5 with that of other HCV genotypes. A subset of HCV-1 infected patients selected from within the study database were selected to match the HCV-5 sample for known prognostic factors. In Belgium HCV-5 is responsible for a significant minority of cases of chronic hepatitis C CHC (4.5%) and is characterized by a more advanced age (58.4 years), a high frequency of cirrhosis (27.7%), a specific mode of HCV acquisition, and a particular geographic origin (66.7% of patients from West Flanders). The primary comparative analysis showed that response to treatment with PEG-INF + RBV of HCV-5 is similar to HCV-1 and lower compared to HCV-2/3. The analysis of the matched patient subgroup demonstrates that the HCV-5 “intrinsic sensitivity” to PEG-IFN + RBV therapy is identical to HCV-1, with a sustained virological response of 55% in both groups. In contrast to previous publications, this meta-analysis suggests that HCV-5 response to treatment is closer to HCV-1 than to HCV-2/3 and suggests that in Belgium HCV-5 infection should be treated with the same antiviral regimen as HCV-1. J. Med. Virol. 83:815–819, 2011. © 2011 Wiley-Liss, Inc.

No comments:

Post a Comment